Start Your Search
Poster Display Session (ID 63)
- Event: ELCC 2017
- Type: Poster Display Session
- Presentations: 1
- Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
167P - Role of surgery in the treatment of thymic carcinoma based on a 5-year experience (ID 325)
12:30 - 13:00 | Author(s): A. Hatibi
Invasive thymomas and thymic carcinomas are relatively rare neoplasms, which together represent about 0.2-1.5% of all malignancies. Thymic carcinomas account for only 0.06% of all thymic neoplasms and have extremely poor prognosis. In about 50% of the patients, thymic carcinomas are detected by chance with plain-film chest radiography. Nowadays the surgery is going to earn more and more space in their multimodality treatment because of new techniques and new technology.
We reviewed all cases with histologically confirmed thymic carcinoma treated between 2011 and 2016. This study was performed to investigate the tumor characteristics, treatment approach, and prognosis of patients with thymic carcinoma.
There were 47% males and 53% females in this study. Mean age was 45,4 years. Thymic carcinoma was diagnosed in 13% of patients with mediastinal tumors, as opposed to 60% for thymoma. None of the thymic carcinoma patients had concomitant myasthenia gravis. All of the patients received surgical intervention and the diagnosis was made by pathologic study. The pathologic subtypes of thymic carcinoma included 40% squamous cell carcinomas, 35% undifferentiated carcinomas, 20% carcinoid tumors, and the rest other types of tumors. Surgery performed was en-bloc resection of the tumor in 22% of cases accompanied by partial resection of superior vena cava, total resection of the left innominate vein and partial pericardectomy, and debulking surgery in 18%. In all other cases surgery was undertaken for diagnostic purposes. No perioperative deaths occurred. All cases were treated postoperatively with adjuvant radio and/or chemotherapy. The mean of hospitalized days after surgery was 12±2.
Owing to the paucity of cases, optimal management of thymic carcinoma has yet to be defined, but one thing is for sure, that it requires multimodality treatment. Our experience supports the pivotal role of surgery in managing thymic carcinoma. En-bloc resection of the tumor is an essential treatment for favorable outcomes of locally advanced thymic tumors, while debulking surgery may be considered for patients in advanced stages because it minimizes the tumour size and area for irradiation postoperatively.
Clinical trial identification:
Legal entity responsible for the study:
All authors have declared no conflicts of interest.